What is Zacks Research’s Forecast for GSK FY2025 Earnings?

GSK plc (NYSE:GSK) – Investment analysts at Zacks Research dropped their FY2025 earnings estimates for shares of GSK in a report released on Wednesday, October 16th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings of $4.45 per share for the year, down from their previous forecast of $4.51. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s Q4 2025 earnings at $0.96 EPS, Q3 2026 earnings at $1.55 EPS and FY2026 earnings at $4.96 EPS.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The company had revenue of $9.95 billion during the quarter, compared to the consensus estimate of $9.49 billion. GSK had a net margin of 12.87% and a return on equity of 51.48%.

Several other equities research analysts have also recently weighed in on the stock. UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group boosted their price objective on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Citigroup raised GSK to a “strong-buy” rating in a report on Monday, June 24th. Finally, Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $50.00.

GSK Stock Performance

NYSE:GSK opened at $38.55 on Monday. The company has a market cap of $79.89 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 1.30 and a beta of 0.65. GSK has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The stock has a fifty day moving average price of $41.44 and a 200-day moving average price of $41.25.

Institutional Trading of GSK

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC lifted its holdings in GSK by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company’s stock worth $481,000 after buying an additional 3,405 shares during the period. Blue Trust Inc. increased its position in GSK by 335.1% during the 3rd quarter. Blue Trust Inc. now owns 10,720 shares of the pharmaceutical company’s stock valued at $413,000 after purchasing an additional 8,256 shares during the period. Aaron Wealth Advisors LLC raised its holdings in GSK by 11.3% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 20,711 shares of the pharmaceutical company’s stock worth $847,000 after purchasing an additional 2,103 shares during the last quarter. Cardinal Capital Management boosted its stake in shares of GSK by 1.5% in the 3rd quarter. Cardinal Capital Management now owns 56,372 shares of the pharmaceutical company’s stock valued at $2,326,000 after purchasing an additional 808 shares during the last quarter. Finally, Global Retirement Partners LLC raised its stake in GSK by 4.3% during the third quarter. Global Retirement Partners LLC now owns 40,110 shares of the pharmaceutical company’s stock worth $1,640,000 after buying an additional 1,664 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The stock was bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.00% of the company’s stock.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Shareholders of record on Friday, August 16th were given a $0.3843 dividend. The ex-dividend date of this dividend was Friday, August 16th. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a yield of 3.99%. GSK’s dividend payout ratio (DPR) is currently 55.80%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.